CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:CoLucid Pharmaceuticals Inc (CLCD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013094
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. It’s been designed to deliver efficacy for the acute treatment of migraine in adults without the vasoconstrictor activity and clinical limitations associated with previous generations of migraine therapies. The company offers oral lasmiditan for the treatment of migraine headaches; and intravenous lasmiditan to treat unspecified headache pain in adults. CoLucid is headquartered in Cambridge, Massachusetts, the US.

CoLucid Pharmaceuticals Inc (CLCD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
CoLucid Pharma Raises USD37 Million in Series C Financing Round 10
CoLucid Pharma Secures An Additional US$4 Million In Venture Financing 12
Partnerships 13
CoLucid Pharma And Ildong Pharma Enter Into Distribution Agreement For Lasmiditan 13
Equity Offering 14
CoLucid Pharma Prices Public Offering of Shares for USD65 Million 14
CoLucid Pharma Raises USD55 Million in IPO 16
Acquisition 17
Eli Lilly Acquires CoLucid Pharma for USD960 Million in Tender Offer 17
CoLucid Pharmaceuticals Inc – Key Competitors 19
CoLucid Pharmaceuticals Inc – Key Employees 20
CoLucid Pharmaceuticals Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Nov 09, 2016: CoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights 22
Aug 10, 2016: CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights 24
May 11, 2016: CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights 25
Mar 02, 2016: CoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CoLucid Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CoLucid Pharma Raises USD37 Million in Series C Financing Round 10
CoLucid Pharma Secures An Additional US$4 Million In Venture Financing 12
CoLucid Pharma And Ildong Pharma Enter Into Distribution Agreement For Lasmiditan 13
CoLucid Pharma Prices Public Offering of Shares for USD65 Million 14
CoLucid Pharma Raises USD55 Million in IPO 16
Eli Lilly Acquires CoLucid Pharma for USD960 Million in Tender Offer 17
CoLucid Pharmaceuticals Inc, Key Competitors 19
CoLucid Pharmaceuticals Inc, Key Employees 20

★海外企業調査レポート[CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Home Depot, Inc.:企業の戦略・SWOT・財務情報
    The Home Depot, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Home Depot, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Revera Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Revera Inc (Revera), formerly Retirement Residences Real Estate Investment Trust, is a healthcare service provider that offers assisted living, independent living, seniors’ apartments,memory care and long term care services. The center provides person-centered care, quality care, clinical pr …
  • BerryPharma AG:企業の戦略・SWOT・財務情報
    BerryPharma AG - Strategy, SWOT and Corporate Finance Report Summary BerryPharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Vaisala oyj (VAIAS):企業の財務・戦略的SWOT分析
    Summary Vaisala oyj (Vaisala) is a manufacturer of industrial and environmental measurement products. Its products include automatic weather stations and sensors, aviation weather systems, wireless temperature and humidity data loggers, indoor monitoring systems, weather radar products, rail weather …
  • Ak Bars Bank:企業の戦略・SWOT・財務分析
    Ak Bars Bank - Strategy, SWOT and Corporate Finance Report Summary Ak Bars Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Southern Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Southern Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Tabuk Pharmaceuticals Manufacturing Company-製薬・医療分野:企業M&A・提携分析
    Summary Tabuk Pharmaceuticals Manufacturing Company (Tabuk), a subsidiary of Astra Industrial Group is a drug company that develops, manufactures and markets branded generic pharmaceuticals and under-licensed products . The company offers products in various therapeutic areas including alimentary tr …
  • Bauhaus International (Holdings) Limited (483):企業の財務・戦略的SWOT分析
    Bauhaus International (Holdings) Limited (483) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • FBD Holdings Plc (EG7):企業の財務・戦略的SWOT分析
    FBD Holdings Plc (EG7) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Napp Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Napp Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Vectren Corp (VVC):企業の財務・戦略的SWOT分析
    Vectren Corp (VVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mission Pharmacal Company:企業の戦略・SWOT・財務情報
    Mission Pharmacal Company - Strategy, SWOT and Corporate Finance Report Summary Mission Pharmacal Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • W&T Offshore Inc (WTI):石油・ガス:M&Aディール及び事業提携情報
    Summary W&T Offshore Inc (W&T Offshore) is an independent oil and natural gas company. It carries out acquisition, exploitation, development and exploration of oil and natural gas assets both onshore and offshore in the Gulf of Mexico. The company acquires rights to explore and develop new prospects …
  • Orion Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Orion Health Inc (Orion) is a healthcare technology company that offers software solutions. The company designs healthcare software for hospitals and health systems. Its products comprise electronic health record, rhapsody integration engine, hospital information system and symphonia messagi …
  • Country Road Group Pty Ltd:企業の戦略的SWOT分析
    Country Road Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Ra Pharmaceuticals Inc (RARX):医療機器:M&Aディール及び事業提携情報
    Summary Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals develops its pipeline products through its proprietary peptide …
  • Daya Materials Bhd (DAYA):企業の財務・戦略的SWOT分析
    Summary Daya Materials Bhd (DMB) is a chemical company that offers polymer compound solutions. The company provides bulk chemicals, catalysts, additives, inert support materials and deodorizing agents. Its polymer compound products include semi conductive compounds, medium-voltage XLPE compounds, lo …
  • NeoPharm Co Ltd:企業の戦略・SWOT・財務情報
    NeoPharm Co Ltd - Strategy, SWOT and Corporate Finance Report Summary NeoPharm Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Indiana University Health Inc:企業の戦略的SWOT分析
    Indiana University Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Lahey Hospital and Medical Center:企業の戦略的SWOT分析
    Lahey Hospital and Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆